Onconetix (FRA:J4T) Ending Cash Position: €5.16 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J4T Onconetix Inc FRA:J4T
21 GF Score
Price €11,985.00
! 4 Warning Signs
View Full Analysis

What is Onconetix Ending Cash Position?

Onconetix FRA:J4T 21 Ending Cash Position is €5.16 Mil as of Jun. 2026. GuruFocus rates FRA:J4T with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

Onconetix's Ending Cash Position for the quarter that ended in Jun. 2026 was €5.16 Mil.

Onconetix's quarterly Ending Cash Position declined from Dec. 2025 (€4.46 Mil) to Mar. 2026 (€3.21 Mil) but then increased from Mar. 2026 (€3.21 Mil) to Jun. 2026 (€5.16 Mil).

Onconetix's annual Ending Cash Position declined from Dec. 2023 (€4.18 Mil) to Dec. 2024 (€0.62 Mil) but then increased from Dec. 2024 (€0.62 Mil) to Dec. 2025 (€4.46 Mil).

Onconetix Ending Cash Position Related Terms

Onconetix Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Onconetix's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onconetix Ending Cash Position Chart

Onconetix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 1.71 24.31 4.18 0.62 4.46

Onconetix Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.71 4.46 3.21 5.16
FRA:J4T
21GF Score
Onconetix Inc FRA:J4T
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onconetix Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Onconetix's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.552+3.907
=4.46

Onconetix's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3.226+1.932
=5.16

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €5.16 Mil mean?
Onconetix (FRA:J4T) has a Ending Cash Position of €5.16 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Onconetix and its competitors.
Is Onconetix's Ending Cash Position too high?
Onconetix's current Ending Cash Position is €5.16 Mil. Overall, Onconetix has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Onconetix's Ending Cash Position compare to OGEN and RNAZ?
Onconetix's Ending Cash Position of €5.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Onconetix and its competitors. Onconetix's current Ending Cash Position is €5.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onconetix stock overvalued right now?
Onconetix (FRA:J4T) has a current Ending Cash Position of €5.16 Mil. The current Ending Cash Position is €5.16 Mil. Onconetix's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Onconetix (FRA:J4T), the current Ending Cash Position is €5.16 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Onconetix Business Description

Other Exchanges ONCO:USA
Address 201 E. Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
21GF Score

Get the complete analysis for FRA:J4T

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11,985.00
Price